ans014004
Small moleculeexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 19, 2024 (NCT06328439)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07285148 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2026 | Avistone Biotechnology Co., Ltd., Beijing Pearl Biotechnology Limited Liability Company |
| NCT06307795 | Phase 1 | Apr 20, 2024 | Avistone Biotechnology Co., Ltd. |
| NCT06328439 | Phase 1 | Mar 19, 2024 | Avistone Biotechnology Co., Ltd., Central South University, Chinese Academy of Medical Sciences, Henan Medical University, Jiao Tong University, Peking University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avistone Biotechnology Co., Ltd. | For profit | 3 | 2 | 2 | 2024 |
| Beijing Pearl Biotechnology Limited Liability Company | Government | 1 | 1 | 1 | 2026 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Henan Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
7 organizations
Page 1 / 1